Find Clinical Trials

September 14, 2022 in Hematology

S1803

S1803: Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct…
Read More
July 11, 2022 in Hematology

S1925

S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small…
Read More
July 11, 2022 in Hematology

S1826

S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (12+ Years Old) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma…
Read More
July 11, 2022 in Hematology

S1712

Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Read More
July 11, 2022 in Hematology

S1608

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Read More
June 30, 2022 in Hematology

GCT3013-05

GCT3013-05: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Read More
June 30, 2022 in Hematology

EAA181

EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (NCT04566328)
Read More
June 30, 2022 in Hematology

EAA173

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Read More
June 30, 2022 in Hematology

EAA171

EAA171: Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Read More
June 30, 2022 in Hematology

EA4181

Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A)…
Read More
June 30, 2022 in Hematology

EA6174

EA6174-A Phase III Randomized Trial Comparing Adjuvant MK-3775 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Read More
June 30, 2022 in Hematology

CONNECT Myeloid

The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Read More
June 30, 2022 in Hematology

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Read More
June 30, 2022 in Hematology

A051701

A051701: Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas
Read More
June 30, 2022 in Hematology

A041701

A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Read More
June 30, 2022 in Hematology

A041501

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly…
Read More